Overview

Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion

Status:
Suspended
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
Female
Summary
A therapeutic abortion is one of the most common procedures performed in Canada, with approximately 100,000 occurring annually. 95% of induced abortions are done surgically, with just over two thirds of these procedures taking place in the first trimester. This study will be a randomized, controlled, double-blinded, single-centre superiority trial with three parallel groups; oral morphine vs intravenous fentanyl vs intravenous ketamine. The primary outcome will be immediate post-operative pain following a first trimester therapeutic abortion as assessed using the visual analogue scale. Randomization will be performed as block randomization with a 1:1:1 allocation ratio. In total, 123 participants will be recruited and randomized, with 41 being assigned to each treatment arm. This study will be conducted at the Women's Clinic at Kingston General Hospital in Kingston, Ontario, Canada. Women from Kingston and the surrounding areas are referred to this clinic and can self-refer for therapeutic abortion. The investogators hope that this research will move us towards a better form of pain control for our participants undergoing first trimester surgical abortion, without increasing length of stay, side effects, or adverse events. This, in turn, will hopefully improve access to optimal pain control to participants undergoing first trimester surgical abortion in an outpatient setting.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Dr. Marie Eve Sophie Bussiere-Cote
Queen's University
Treatments:
Fentanyl
Ketamine
Morphine
Criteria
Inclusion Criteria:

1. Confirmed first trimester pregnancy with an ultrasound showing a viable intrauterine
pregnancy with a gestational age of less than 12 weeks since the last menstrual period

2. Unwanted pregnancy and consented to undergo a first trimester surgical abortion

Exclusion Criteria:

1. Age <18 years at the time of study enrollment

2. Known allergy or sensitivity to any of the medications used in the study

3. Any serious medical comorbidity that would make IV sedation contraindicated in an
outpatient setting (ex. Heart disease, lung disease)